Lisinopril-induced cough
Pro Research Analysisby 
Searched over 200M research papers for "lisinopril-induced cough"
Incidence and Risk Factors of Lisinopril-Induced Cough
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is well known to cause a persistent, dry cough in a significant number of patients. Studies consistently report that the incidence of cough with lisinopril ranges from about 8% to nearly 69% in patients with a history of ACE inhibitor-induced cough, which is much higher than with other antihypertensive agents such as angiotensin receptor blockers (ARBs) or calcium channel blockers (CCBs) Os1994Os1992Benz1997+4 MORE. The cough is typically described as dry, nonproductive, and persistent, often starting within the first week of therapy and resolving within days to weeks after discontinuation of the drug Nazir2016Just1989.
Gender and Smoking Status as Risk Factors
Research shows a clear gender difference in the risk of developing lisinopril-induced cough. Women are significantly more likely to report this side effect than men, with rates as high as 12.6% in women compared to 4.4% in men Os1994Os1992. Additionally, nonsmokers are more likely to experience cough than smokers .
Comparison with Other Antihypertensive Agents
Lisinopril and other ACE inhibitors are associated with a much higher risk of cough compared to ARBs (such as valsartan, losartan, and telmisartan), CCBs (such as nifedipine), and placebo. For example, the incidence of cough with lisinopril is significantly higher than with valsartan (68.9% vs. 19.5%), losartan (87.5% vs. 36.7%), telmisartan (60% vs. 15.6%), and placebo (as low as 3.1% to 9.7%) Os1994Benz1997Lacourciére1999+2 MORE. The risk of cough is also higher with lisinopril compared to other ACE inhibitors, but all ACE inhibitors share this side effect to some degree Nazir2016Lacourcière1995.
Mechanism of Lisinopril-Induced Cough
The cough is believed to be caused by the accumulation of bradykinin and substance P, which are normally broken down by ACE. Lisinopril inhibits this breakdown, leading to increased levels of these mediators, which stimulate cough reflex pathways in the lungs and central nervous system Cinelli2015Nazir2016Just1989. Experimental studies in animals have shown that lisinopril can directly increase the cough reflex through central mechanisms involving bradykinin and substance P .
Clinical Implications and Management
Lisinopril-induced cough can be bothersome enough to lead to discontinuation of therapy in some patients . The cough usually resolves within 1 to 4 weeks after stopping the medication . For patients who develop this side effect, switching to an ARB or a CCB is recommended, as these alternatives have a much lower risk of causing cough and provide similar blood pressure control Benz1997Lacourciére1999Hu2023+1 MORE.
Conclusion
Lisinopril-induced cough is a common and well-documented side effect, especially in women and nonsmokers. The cough is dry, persistent, and related to the accumulation of bradykinin and substance P. ARBs and CCBs are effective alternatives for patients who cannot tolerate ACE inhibitors due to cough. Recognizing and managing this side effect is important for optimizing hypertension treatment and patient comfort.
Sources and full results
Most relevant research papers on this topic